{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:47:29Z","timestamp":1793317649948,"version":"4.5.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009930","name":"Basilea Pharmaceutica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009930","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007343","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007343","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018720","name":"Advanced Accelerator Applications","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018720","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010544","name":"Exelixis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010544","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011218","name":"Sandoz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011218","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016939","name":"Myriad Genetics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016939","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.esmoop.2022.100529","type":"journal-article","created":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T20:05:49Z","timestamp":1657310749000},"page":"100529","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":75,"title":["A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202)"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1127-9919","authenticated-orcid":false,"given":"S.","family":"Rao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1616-0335","authenticated-orcid":false,"given":"G.","family":"Anandappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Capdevila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Dahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9537-6454","authenticated-orcid":false,"given":"L.","family":"Evesque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2851-7119","authenticated-orcid":false,"given":"S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.P.","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1859-7012","authenticated-orcid":false,"given":"D.C.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0020-1537","authenticated-orcid":false,"given":"L.H.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Samalin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8781-3212","authenticated-orcid":false,"given":"K.-L.","family":"Spindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7087-9116","authenticated-orcid":false,"given":"S.","family":"Tamberi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2886-6650","authenticated-orcid":false,"given":"A.","family":"Demols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0593-0218","authenticated-orcid":false,"given":"M.G.","family":"Guren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6554-5488","authenticated-orcid":false,"given":"M.","family":"Fakih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Kayyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Cornfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Catlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3921-2479","authenticated-orcid":false,"given":"J.-P.","family":"Spano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.esmoop.2022.100529_bib1","first-page":"924","article-title":"International trends in anal cancer incidence rates","volume":"46","author":"Islami","year":"2017","journal-title":"Int J Epidemiol"},{"issue":"10","key":"10.1016\/j.esmoop.2022.100529_bib2","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/1055-9965.EPI-15-0044","article-title":"Anal cancer incidence in the United States, 1977-2011: distinct patterns by histology and behavior","volume":"24","author":"Shiels","year":"2015","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3","key":"10.1016\/j.esmoop.2022.100529_bib3","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"10.1016\/j.esmoop.2022.100529_bib4","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.dld.2017.05.011","article-title":"Anal cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SNFCP)","volume":"49","author":"Moureau-Zabotto","year":"2017","journal-title":"Dig Liver Dis"},{"issue":"12","key":"10.1016\/j.esmoop.2022.100529_bib5","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1200\/JCO.2012.45.2524","article-title":"Changing patterns of anal canal carcinoma in the United States","volume":"31","author":"Nelson","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2022.100529_bib6","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1002\/ijc.27650","article-title":"EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease","volume":"131","author":"Arbyn","year":"2012","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2022.100529_bib7","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4103\/2229-516X.179027","article-title":"Human papillomavirus-associated cancers: a growing global problem","volume":"6","author":"Bansal","year":"2016","journal-title":"Int J Appl Basic Med Res"},{"issue":"5","key":"10.1016\/j.esmoop.2022.100529_bib8","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1080\/07357900600815208","article-title":"Anal cancer: current and future methodology","volume":"24","author":"Eng","year":"2006","journal-title":"Cancer Invest"},{"issue":"35","key":"10.1016\/j.esmoop.2022.100529_bib9","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1200\/JCO.2012.43.8085","article-title":"Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil\/mitomycin versus fluorouracil\/cisplatin","volume":"30","author":"Gunderson","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2022.100529_bib10","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1470-2045(13)70086-X","article-title":"Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2\u00a0\u00d7 2 factorial trial","volume":"14","author":"James","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2022.100529_bib11","series-title":"NCCN Clinical Practice Guidelines in Oncology: Anal Carcinoma. Version 2.2020","year":"2020"},{"issue":"7","key":"10.1016\/j.esmoop.2022.100529_bib12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11912-018-0698-6","article-title":"Systemic therapies for advanced squamous cell anal cancer","volume":"20","author":"Sclafani","year":"2018","journal-title":"Curr Oncol Rep"},{"issue":"9","key":"10.1016\/j.esmoop.2022.100529_bib13","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.annonc.2021.06.015","article-title":"Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Rao","year":"2021","journal-title":"Ann Oncol"},{"issue":"22","key":"10.1016\/j.esmoop.2022.100529_bib14","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1200\/JCO.19.03266","article-title":"International rare cancers initiative multicenter randomized phase II trial of cisplatin and fluorouracil versus carboplatin and paclitaxel in advanced anal cancer: InterAAct","volume":"38","author":"Rao","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2022.100529_bib15","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(18)30321-8","article-title":"Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2022.100529_bib16","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920975356","article-title":"Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinoma","volume":"12","author":"Kim","year":"2020","journal-title":"Ther Adv Med Oncol"},{"issue":"16","key":"10.1016\/j.esmoop.2022.100529_bib17","doi-asserted-by":"crossref","first-page":"6853","DOI":"10.1002\/cam4.2558","article-title":"Mitomycin and 5-fluorouracil for second-line treatment of metastatic squamous cell carcinomas of the anal canal","volume":"8","author":"Saint","year":"2019","journal-title":"Cancer Med"},{"issue":"2","key":"10.1016\/j.esmoop.2022.100529_bib19","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/cncr.20365","article-title":"Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer","volume":"101","author":"Daling","year":"2004","journal-title":"Cancer"},{"issue":"19","key":"10.1016\/j.esmoop.2022.100529_bib20","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1056\/NEJM199711063371904","article-title":"Sexually transmitted infection as a cause of anal cancer","volume":"337","author":"Frisch","year":"1997","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.esmoop.2022.100529_bib21","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ygyno.2009.05.006","article-title":"Presumed previous human papillomavirus (HPV) related gynecological cancer in women diagnosed with anal cancer in the province of Ontario","volume":"114","author":"Jim\u00e9nez","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2022.100529_bib22","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/ijc.25080","article-title":"Immunosuppressive disorders and risk of anal squamous cell carcinoma: a nationwide cohort study in Denmark, 1978-2005","volume":"127","author":"Sunesen","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.esmoop.2022.100529_bib23","doi-asserted-by":"crossref","first-page":"201","DOI":"10.20517\/2394-4722.2015.67","article-title":"The role of human papillomaviruses in cancer progression","volume":"2","author":"Tulay","year":"2016","journal-title":"J\u00a0Cancer Metastasis Treat"},{"key":"10.1016\/j.esmoop.2022.100529_bib24","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.virusres.2016.11.023","article-title":"Evasion of host immune defenses by human papillomavirus","volume":"231","author":"Westrich","year":"2017","journal-title":"Virus Res"},{"key":"10.1016\/j.esmoop.2022.100529_bib25","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3389\/fphar.2018.00536","article-title":"Regulation of PD-L1: emerging routes for targeting tumor immune evasion","volume":"9","author":"Wang","year":"2018","journal-title":"Front Pharmacol"},{"issue":"19","key":"10.1016\/j.esmoop.2022.100529_bib26","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"10167","key":"10.1016\/j.esmoop.2022.100529_bib27","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2022.100529_bib28","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.esmoop.2022.100529_bib29","doi-asserted-by":"crossref","first-page":"P940","DOI":"10.1016\/j.annonc.2021.04.009","article-title":"EMPOWER-Cervical 1\/GOG-3016\/ENGOT-cx9: interim analysis of phase III trial of cemiplimab vs. investigator\u2019s choice (IC) chemotherapy (chemo) in recurrent\/metastatic (R\/M) cervical carcinoma","volume":"32","author":"Tewari","year":"2021","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2022.100529_bib30","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1470-2045(17)30104-3","article-title":"Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study","volume":"18","author":"Morris","year":"2017","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2022.100529_bib31","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/annonc\/mdx029","article-title":"Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal","volume":"28","author":"Ott","year":"2017","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2022.100529_bib32","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S2468-1253(21)00382-4","article-title":"Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study","volume":"7","author":"Marabelle","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"suppl 13","key":"10.1016\/j.esmoop.2022.100529_bib33","article-title":"Assessment of flat dosing strategy for INCMGA00012 in patients with advanced tumors","volume":"79","author":"Chen","year":"2019","journal-title":"Cancer Res"},{"issue":"13","key":"10.1016\/j.esmoop.2022.100529_bib34","article-title":"Pharmacodynamic correlates in a phase I study of INCMGA00012, a PD-1 antagonistic monoclonal antibody","volume":"79","author":"Condamine","year":"2019","journal-title":"Cancer Res"},{"issue":"87","key":"10.1016\/j.esmoop.2022.100529_bib35","article-title":"Preclinical characterization of MGA012, a novel clinical-stage PD-1 monoclonal antibody","volume":"5","author":"La Motte-Mohs","year":"2017","journal-title":"J\u00a0ImmunoTher Cancer"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2022.100529_bib36","article-title":"First-in-human phase 1 study of INCMGA00012 in patients with advanced solid tumors: interim results of the cohort expansion phase","volume":"6","author":"Mehnert","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2022.100529_bib37","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.radonc.2017.11.018","article-title":"Phase I-III development of the EORTC QLQ-ANL27, a health-related quality of life questionnaire for anal cancer","volume":"126","author":"Sodergren","year":"2018","journal-title":"Radiother Oncol"},{"issue":"17","key":"10.1016\/j.esmoop.2022.100529_bib38","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2022.100529_bib39","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1158\/2326-6066.CIR-16-0325","article-title":"Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC","volume":"5","author":"Tumeh","year":"2017","journal-title":"Cancer Immunol Res"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2022.100529_bib40","article-title":"A\u00a0phase 1 study of INCMGA00012, a PD-1 inhibitor, in patients with advanced solid tumors: preliminary results for patients with advanced cervical cancer (POD1UM-101)","volume":"7","author":"Mehnert","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"issue":"14","key":"10.1016\/j.esmoop.2022.100529_bib41","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1200\/JCO.2016.70.1524","article-title":"Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study","volume":"35","author":"Bauml","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"10.1016\/j.esmoop.2022.100529_bib42","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study","volume":"37","author":"Chung","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2022.100529_bib43","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.annonc.2020.04.001","article-title":"Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study","volume":"31","author":"Ferris","year":"2020","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2022.100529_bib44","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ygyno.2020.08.026","article-title":"PD-1 blockade in recurrent or metastatic cervical cancer: data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer","volume":"159","author":"Rischin","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2022.100529_bib45","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1002\/ijc.28411","article-title":"The interplay between HPV and host immunity in head and neck squamous cell carcinoma","volume":"134","author":"Andersen","year":"2014","journal-title":"Int J Cancer"},{"issue":"7","key":"10.1016\/j.esmoop.2022.100529_bib46","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1158\/0008-5472.CAN-09-4299","article-title":"An unexpectedly large polyclonal repertoire of HPV-specific T cells is poised for action in patients with cervical cancer","volume":"70","author":"de Vos van Steenwijk","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2022.100529_bib47","series-title":"TECENTRIQ (atezolizumab) [package insert]","year":"2021"},{"key":"10.1016\/j.esmoop.2022.100529_bib48","series-title":"KEYTRUDA (pembrolizumab) [package insert]","year":"2020"},{"key":"10.1016\/j.esmoop.2022.100529_bib49","year":"2022"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2022.100529_bib50","article-title":"Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): results from the multicohort, phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2022.100529_bib51","doi-asserted-by":"crossref","first-page":"S412","DOI":"10.1016\/j.annonc.2020.08.513","article-title":"Final results of the CARACAS study: randomized phase II trial of avelumab alone or with cetuximab for unresectable, locally advanced or metastatic squamous cell anal carcinoma progressed to at least one line of treatment","volume":"31","author":"Lonardi","year":"2020","journal-title":"Ann Oncol"},{"issue":"suppl 15","key":"10.1016\/j.esmoop.2022.100529_bib52","doi-asserted-by":"crossref","first-page":"Abs 4020","DOI":"10.1200\/JCO.2020.38.15_suppl.4020","article-title":"Pembrolizumab for previously treated advanced anal squamous cell carcinoma: pooled results from the KEYNOTE-028 and KEYNOTE-158 studies","volume":"38","author":"Marabelle","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2022.100529_bib53","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2022.100529_bib54","first-page":"299","article-title":"Outcomes of patients with metastatic anal cancer according to HIV infection: a multicenter study by the Latin American Gastrointestinal Oncology Group (SLAGO)","volume":"20","author":"Mattos","year":"2021","journal-title":"Clin Colorectal Cancer"},{"issue":"33","key":"10.1016\/j.esmoop.2022.100529_bib55","doi-asserted-by":"crossref","first-page":"3774","DOI":"10.1200\/JCO.2017.73.7338","article-title":"Modernizing clinical trial eligibility criteria: recommendations of the American Society of Clinical Oncology\u2013Friends of Cancer Research HIV Working Group","volume":"35","author":"Uldrick","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2022.100529_bib56","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"issue":"6411","key":"10.1016\/j.esmoop.2022.100529_bib57","doi-asserted-by":"crossref","first-page":"eaar3593","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for\u00a0PD-1 checkpoint blockade-based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922001508?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922001508?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:28:51Z","timestamp":1761856131000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702922001508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S2059702922001508"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100529","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202)","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100529","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100529"}}